Skip to main content

Table 4 BAL cytological pattern, lung function tests parameters, laboratory results, % of patients on treatment and time from first symptoms to visit 1 in sarcoidosis patients divided according to radiological stage.

From: Exhaled 8-isoprostane as a prognostic marker in sarcoidosis. A short term follow-up

 

Stage I

Stage II

Stage III

Difference

BAL lymphocytes (%)

29.6 ± 3.5

34.9 ± 7.3

32.8 ± 7.0

NS

BAL lymphocytes (× 104/mL)

5.03 ± 1.08

8.5 ± 2.7

10.98 ± 4.15

NS

BAL neutrophils (%)

1 ± 0.33

(1) [0-1]

1.13 ± 0.4

(1) [0-2]

0.33 ± 0.21

(0) [0-5]

NS

BAL neutrophils

(× 104/mL)

0.15 ± 0.06

0.22 ± 0.08

0.23 ± 0.22

NS

BAL eosinophils (%)

1.17 ± 0.25

(1) [0.5-1.5]

0.75 ± 0.25

(1) [0-1]

0.72 ± 0.32

(1) [0-5]

NS

BAL eosinophils

(× 104/mL)

0.14 ± 0.03

0.16 ± 0.25

0.72 ± 0.32

p ≤ 0.01: I vs III

p ≤ 0.05: II vs III

FEV1 (% predicted)

99.4 ± 3.5

81.1 ± 7.5

87.8 ± 7.0

p ≤ 0.05: I vs II

FVC (% predicted)

104.7 ± 3.5

84.8 ± 7.0

94.9 ± 4.0

p ≤ 0.05: I vs II

FEV1/FVC (%)

0.83 ± 0.02

0.78 ± 0.04

0.77 ± 0.04

NS

DLCOc (% predicted)

96.8 ± 4.4

77.4 ± 6.0

77.1 ± 6.3

p ≤ 0.05: I vs II&III

SACE (IU/L)

65.8 ± 8.6

98.8 ± 30.3

45.8 ± 12.8

NS

S-Ca2+(mmol/L)

2.46 ± 0.02

2.44 ± 0.08

2.50 ± 0.02

NS

U-Ca2+(mmol/24 h)

5.25 ± 0.48

5.15 ± 0.94

4.52 ± 0.83

NS

CRP (mg/L)

7.30 ± 2.27

(5.0)

[1.5-7.1]

19.85 ± 8.77

(9.4)

[4.6-25.3]

4.40 ± 1.71

(2.5)

[0.7-6.7]

NS

T from onset to V1

(weeks)

38 ± 25

(8) [4-24]

107 ± 50

(8) [4-238]

149 ± 55

(88) [18-289]

p ≤ 0.05: I vs III

LS

15/23

5/9

0/8

-

  1. DLCOc -- diffusion capacity for CO corrected for hemoglobin, FEV1 -- forced expiratory volume in 1st second of expiration, FVC -- forced vital capacity,
  2. LS -- Löfgren syndrome, S -- serum, SACE -- serum angiotensin converting enzyme, T -- time, U -- urine, V1 -- visit 1.